ChiCTR2100044123 版本V1.0 版本创建时间2021/07/18 00:26:09 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100044123 

最近更新日期:

Date of Last Refreshed on:

2021-03-11 10:43:33 

注册时间:

Date of Registration:

2021-03-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

膜型和可溶性B7H4/B7H5在急性胰腺炎和脓毒症疾病过程中的变化及机制研究

Public title:

The Role of Human mB7H4/B7H5 and sB7H4/B7H5 in Inflammatory Responses of Acute Pancreatitis and Sepsis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

急诊医学科

Scientific title:

emergency department

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龚菊 

研究负责人:

龚菊 

Applicant:

GongJu 

Study leader:

GongJu 

申请注册联系人电话:

Applicant telephone:

+8613913699885

研究负责人电话:

Study leader's
telephone:

+8613913699885

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

44707879@qq.com

研究负责人电子邮件:

Study leader's E-mail:

44707879@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

常熟市第二人民医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

常熟市中南锦苑1-1501

研究负责人通讯地址:

常熟市中南锦苑1-1501

Applicant address:

HaiYu Road NO.68,ChangShu,JiangSu Province,China

Study leader's address:

HaiYu Road NO.68,ChangShu,JiangSu Province,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

常熟市第二人民医院

Applicant's institution:

常熟市第二人民医院

研究负责人所在单位:

常熟市第二人民医院

Affiliation of the Leader:

常熟市第二人民医院

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2021)伦研批第008号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

苏州大学附属第一医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First Affiliated Hospital of Soochow University

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

朱雪松

Contact Name of the ethic committee:

XuesongZhu

伦理委员会联系地址:

苏州大学附属第一医院 姑苏区平海路 899号

Contact Address of the ethic committee:

The first affiliated Hospital of Soochow University, Suzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

常熟市第二人民医院

Primary sponsor:

The Affiliated Changshu Hospital of Xuzhou Medical University

研究实施负责(组长)单位地址:

江苏省常熟市海虞南路68号

Primary sponsor's address:

HaiYu Road NO.68,ChangShu,JiangSu Province,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

常熟市第二人民医院

具体地址:

中南锦苑1-1501

Institution
hospital:

emergency department

Address:

68 Haiyu Road, Changshu

经费或物资来源:

课题赞助

Source(s) of funding:

Project funding

研究疾病:

脓毒症,胰腺炎  

Target disease:

Acute Pancreatitis and Sepsis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

明确共信号分子B7-H4/B7-H5在脓毒症及胰腺炎中的表达,研究其可能的调节机制。  

Objectives of Study:

To clarify the expression of common signaling molecule B7-H4/B7-H5 in sepsis and acute pancreatitis, and to investigate its possible regulatory mechanism.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

18-80岁
符合脓毒症诊断标准
符合急性胰腺炎诊断标准

Inclusion criteria

18-80 years
Conformed to the diagnostic criteria of sepsis
Met the diagnostic criteria for acute pancreatitis

排除标准:

肿瘤
免疫系统疾病

Exclusion criteria:

Tumor
Diseases of the immune system

研究实施时间:

Study execute time:

From 2021-03-06 00:00:00 To 2022-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-03-06 00:00:00 To 2022-03-06 00:00:00

干预措施:

Interventions:

组别:

胰腺炎

样本量:

100

Group:

acute pancreatitis

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

常熟市第二人民医院 

单位级别:

三乙 

Institution
hospital:

emergency department

Level of the institution:

Tertiary B

测量指标:

Outcomes:

指标中文名:

B7H4/B7H5

指标类型:

主要指标

Outcome:

B7H4/B7H5

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究者采用分层随机将患者分配至试验组和对照组

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients were assigned to the trial group and the control group by stratified randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

07,30,2022 www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

07,30,2022 www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-03-11 10:43:34